Cholangiocarcinoma Medication

Updated: Jan 12, 2022
  • Author: Peter E Darwin, MD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print
Medication

Medication Summary

Few patients are diagnosed with early-stage resectable tumors. Guidelines for unresectable or metastatic disease include various chemotherapy regimens. Targeted agents are available as second-line therapy for cholangiocarcinoma with specific driver mutations, including fibroblast growth factor receptor 2 (FGFR2)–selective tyrosine kinase inhibitors for advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement, and an isocitrate dehydrogenase 1 (IDH1) inhibitor for IDH1-mutated cholangiocarcinoma.

Next:

FGFR Inhibitors

Class Summary

Inhibition of FGFR disrupts tumor cell proliferation, survival, migration, and angiogenesis.

Pemigatinib (Pemazyre)

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2, and 3 by inhibiting FGFR1-3 phosphorylation and signaling. Indicated for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Infigratinib (Truseltiq)

Infigratinib is indicated for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. 

Previous